Comparative Pharmacology
Head-to-head clinical analysis: CEFIZOX IN DEXTROSE 5 IN PLASTIC CONTAINER versus ZINACEF IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFIZOX IN DEXTROSE 5 IN PLASTIC CONTAINER versus ZINACEF IN PLASTIC CONTAINER.
CEFIZOX IN DEXTROSE 5% IN PLASTIC CONTAINER vs ZINACEF IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ceftizoxime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It has broad-spectrum activity against gram-positive and gram-negative bacteria.
Cefuroxime is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby blocking transpeptidation and leading to cell lysis and death.
1-2 g IV every 8-12 hours; maximum 12 g/day
750 mg intravenously or intramuscularly every 8 hours; for severe infections, 1.5 g intravenously every 8 hours.
None Documented
None Documented
1.5–2 hours in normal renal function; extends to 20–30 hours in ESRD. Dose adjustment required for CrCl <50 mL/min.
Terminal elimination half-life is approximately 1.5 hours in adults with normal renal function; prolonged to 3-4 hours in neonates and up to 20-30 hours in end-stage renal disease.
Renal: 80–90% unchanged via glomerular filtration and tubular secretion. Biliary/fecal: <10%.
Approximately 80-90% of the dose is excreted unchanged in the urine via glomerular filtration and tubular secretion; the remainder is eliminated via bile and feces.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic